News

The neurotechnology market opportunity for treating Parkinson’s disease has been dominated by deep-brain stimulation systems. But in recent months, some new neurotech therapies exploiting other forms of neuromodulation have emerged from two research teams in Asia. A team of researchers from Japan has developed a novel neuromodulation approach that features gait-combined closed-loop transcranial electrical stimulation.

The potential market for treating diabetes has proven to be an elusive, though alluring target for bioelectronic medicine vendors. The dearth of effective therapies for advanced type 2 diabetes represents one of the greatest unmet medical needs of our generation. Several bioelectronic medicine startups, including MetaCure, Cyberonics (now LivaNova), EnteroMedics (now ReShape LifeSciences), Intrapac…

Tom Oxley to Keynote Seventh Annual Bioelectronic Medicine Forum in NYC Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that the Tom Oxley, the CEO of Synchron Inc., will keynote the Seventh Annual Bioelectronic Medicine Forum. Synchron’s internationally acclaimed stentrode device can record brain activity from within a blood vessel.

In the 20-plus years that we’ve been publishing this newsletter, we’ve devoted considerable coverage to emerging and established neurotech firms, and the entrepreneurs and investors who’ve made those concerns successful. Where we may not have devoted enough ink—or shall we say pixels, since we ceased mailing printed copies in 2023—is to the scientific and clinical investigators who have moved the neurotechnology field forward.

The neurotechnology market opportunity for treating Alzheimer’s disease has shown steady progress in recent months as several commercial firms and research organizations have reported advances. Some well publicized setbacks from pharmaceutical firms in this space have also contributed to a new sense of optimism for device interventions. Many investigators and entrepreneurs in this space have chosen…

Neurotech Reports, the publisher of this newsletter, announced the winners of the 2023 Gold Electrode Awards during the 2023 Neurotech Leaders Forum, which took place in November in San Francisco. The award for best new product went to Neuromod Devices for its Lenire system for treating tinnitus. The award for most promising startup went to Salvia BioElectronics, which is developing a new minimally invasive neuromodulation system for migraine.

The bioelectronic medicine market for treating bowel and bladder disorders underwent a significant transformation earlier this month with the news of the largest M&A deal in the industry’s history. On January 8, Axonics, Inc. announced that it has entered into a definitive agreement to be acquired . for $71 in cash per share, representing an equity value of approximately $3.7 billion. Axonics brings a complementary product portfolio to the Boston Scientific urology business.

The dissemination of bioelectronic medicine therapies is based, to a large extent, on ambulatory surgery centers that perform a majority of minimally invasive surgeries, including medical device implantation and replacement. Implantation procedures performed at ASCs are typically less expensive than those performed at hospitals. As one example, surgery for implanting SNS devices made (CPT codes 645…

The field of noninvasive neuromodulation has witnessed significant growth in recent years, with hundreds of companies targeting various disorders such as pain, vestibular disorders, tinnitus, Alzheimer’s, and various wellness conditions. While the majority of these companies utilize electrical stimulation, other modalities, including magnetic, ultrasound, and optical, have also been explored. More…

The North American Neuromodulation Society opened 2024 with a celebration of its 30th anniversary. The conference has grown over its lifetime from a few hundred attendees in its infancy to more than 3000 in attendance this year. A significant factor in the society’s growth has been the inclusion of novel program elements including several pre-conference workshops ranging from cadaver labs to commercially oriented programs such as i3—Invention, Investment, and Invigoration.